Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 7 art units • 12 examiners • 0 of 14 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Antecip Bioventures Ii LLC currently manages 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 12 distinct examiners, which suggests a high degree of individual examiner variety relative to the total volume of pending matters. The 7 distinct art units involved indicate that the company's intellectual property spans multiple specialized examination groups, requiring a strategy that accounts for diverse procedural nuances within the patent office.
Among the active personnel, Tran, Susan T is identified as the busiest examiner, currently overseeing 2 of the pending office actions. This specific concentration of 2 actions with one individual contrasts with the broader distribution across the 12 distinct examiners assigned to the portfolio. For a practitioner, the presence of 14 pending office actions across 7 distinct art units necessitates a versatile approach to prosecution, as each unit may apply different interpretations of Biotechnology & Pharmaceuticals guidelines.
The fact that 12 distinct examiners are handling the portfolio implies that most examiners are only managing a single case for this entity. This lack of examiner overlap, with the exception of Tran, Susan T and her 2 pending actions, means that institutional knowledge gained from one prosecution may not frequently carry over to others. Consequently, the pending office actions represent a fragmented landscape where individual examiner preferences will likely dictate the pace and outcome of the majority of the applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (14%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting only | 5 (36%) |
| Double-patenting + other | 5 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 2 | 62.8% | +35.1% |
| VALENROD, YEVGENY | 2 | 72.6% | +25.1% |
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19533064 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | AULAKH, CHARANJIT | — |
| 19464471 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18923576 | TREATMENT OF DEPRESSION | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19270315 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | TRAN, SUSAN T | 5d |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 22d |
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | MOU, LIYUAN | — |
| 18988447 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | YOUNG, MICAH PAUL | — |
| 18984644 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | STEVENS, MARK V | — |
| 18778708 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | TRAN, SUSAN T | — |
| 18435115 | METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS | HAVLIN, ROBERT H | — |
| 18531590 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1629 | 2 |
| 1621 | 1 |
| 1622 | 1 |
| 1615 | 1 |
| 1626 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19684927 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | WEDDINGTON, KEVIN E | 1629 | §112 | Non-Final OA | — | Pending | May 21, 2026 |
| 19533064 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | AULAKH, CHARANJIT | 1621 | §103§112DP | Final Rejection | — | Pending | Feb 06, 2026 |
| 19464471 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | INAM, SAHAR | 1622 | §112DP | Non-Final OA | — | Pending | Jan 29, 2026 |
| 19270315 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | TRAN, SUSAN T | 1615 | DP | Non-Final OA | 5d | Pending | Jul 15, 2025 |
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | MOU, LIYUAN | 1629 | §103§112DP | Non-Final OA | — | Pending | May 27, 2025 |
| 18988447 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | YOUNG, MICAH PAUL | — | §102§103DP | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18984644 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | STEVENS, MARK V | — | DP | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18923576 | TREATMENT OF DEPRESSION | KIM, SEONG JONG | — | §102§103DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18778708 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | TRAN, SUSAN T | — | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18435115 | METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS | HAVLIN, ROBERT H | 1626 | §102Other | Final Rejection | — | Pending | Feb 07, 2024 |
| 18531590 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 1628 | DP | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 1628 | DP | Final Rejection | 22d | Pending | Dec 02, 2022 |
| 17937948 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | HUTTER, GILLIAN A | 1625 | §103 | Non-Final OA | — | Pending | Oct 04, 2022 |
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | BARSKY, JARED | 1628 | §103Other | Final Rejection | 22d overdue | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial